Wegovy (semaglutide) NDC 0169-4915

Product information

Brand name (proprietary)

Wegovy

Generic name (nonproprietary)

semaglutide

Active ingredients

Semaglutide — 3.2 mg/mL

Dosage form

Injection, Solution

Route

Subcutaneous

Labeler

Novo Nordisk Pharmaceutical Industries, LP

Product type

Prescription drug

Marketing category

NDA — New Drug ApplicationApplication NDA 215256

Marketing start

Jun 5, 2021

Listing expires

Dec 31, 2027

Other FDA classes

Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)

Identifiers

Product ID 0169-4915_f7b108b9-f276-4e32-84e7-e828ba145da5SPL ID f7b108b9-f276-4e32-84e7-e828ba145da5

Pharmacologic class

GLP-1 Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

No drug-specific HCPCS code in Med-Code’s directory for this product.

Med-Code's directory has no drug-specific HCPCS code for Wegovy. It is usually self-administered and billed by NDC through a pharmacy benefit. Wegovy tablets are pharmacy-dispensed and have no HCPCS code.

If a payer accepts an unclassified code for it in a clinical setting, that would be J3490 (Unclassified drugs), with the NDC, quantity and often the invoice. Acceptance varies by payer.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

Product label

The FDA listing for this product does not reference a label (SPL) set.

Other NDCs under NDA 215256

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.